Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
New facility at Pusa Road expands advanced diagnostic, theranostics, and treatment-planning capabilities across oncology, cardiology, neurology, and nephrology
The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
The company’s Growth Portfolio delivered $6.2 billion in revenue
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
Subscribe To Our Newsletter & Stay Updated
